Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

YSG
$3.57 -0.13 (-3.51%)
🚫 Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares does not pay dividends

Company News

Yatsen's Cash Raise Fuels Erno Laszlo Speculation
Benzinga • Bamboo Works • May 29, 2026

Chinese skincare and cosmetics maker Yatsen Holding completed the first tranche of a $120 million convertible note offering, with speculation that the funds could be used to acquire the struggling Erno Laszlo skincare brand, which was purchased by a Chinese investment group this week for $44 million. Both transactions involve private equity firm ...

Yatsen (YSG) Q4 2024 Earnings Call Transcript
The Motley Fool • The Motley Fool • February 25, 2025

Yatsen, a Chinese beauty company, reported its Q4 2024 earnings. The company saw revenue growth in its skincare and color cosmetics brands, with improved profitability. The company is focused on balancing growth and profitability through brand equity, R&D, and operational efficiency.

Yatsen (YSG) Q3 2024 Earnings Call Transcript
The Motley Fool • The Motley Fool • November 20, 2024

Yatsen, a Chinese beauty company, reported its Q3 2024 earnings. The company faced challenges in the beauty industry, with beauty sales declining while the overall retail market grew. However, Yatsen's skin care brands saw a 3.6% year-over-year increase in net revenues, driven by its clinical and premium skin care brands. The company is focused o...

Yatsen (YSG) Q1 2024 Earnings Call Transcript
The Motley Fool • [email protected] (Motley Fool Transcribing) • May 22, 2024

YSG earnings call for the period ending March 31, 2024.

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga • Avi Kapoor • April 15, 2024

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms. Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday. Here are...

Related Companies